



KAREN L. SMITH, MD, MPH
Director & State Health Officer

State of California—Health and Human Services Agency
California Department of Public Health



GAVIN NEWSOM
Governor

Office of AIDS (OA)

AIDS Drug Assistance Program (ADAP)

Management Memorandum

Memorandum Number: 2019-04

DATE: **March 4, 2019**

TO: **ADAP ENROLLMENT WORKERS**

SUBJECT: **ADDITION OF GENERIC EFAVIRENZ TO THE ADAP FORMULARY**

Effective February 25, 2019, copay coverage for generic efavirenz became available to ADAP clients with private insurance or Medicare with a valid prescription. Efavirenz, which is the generic form of Sustiva®, is a non-nucleoside reverse transcriptase inhibitor indicated for use to treat HIV-1 infection in combination with other antiretroviral medications. Many healthcare plans have added generic efavirenz to their plan formularies and require its use over the brand named Sustiva®. The ADAP Medical Advisory Committee voted to recommend the addition of generic efavirenz to the ADAP formulary for insurance copay coverage effective on February 25th.

Please note that ADAP will only cover the copay cost of efavirenz. ADAP management requests that you share this information with your clinical leadership team and local prescribers. The ADAP drug formulary has been updated to reflect the addition of generic efavirenz, for more information please visit the [ADAP formulary](https://cdph.magellanrx.com/member/documents) webpage (<https://cdph.magellanrx.com/member/documents>).

If you have any questions regarding the addition of this drug to the ADAP formulary, please contact Cynthia Reed-Aguayo, ADAP Specialist, at (916) 449-5791.

Sincerely,

Sandra Robinson, MBA
Chief, ADAP Branch
Office of AIDS